Biotech company Partner Therapeutics Inc (PTx) said on Tuesday that Leukine will be assessed in the SARPAC trial in patients with acute hypoxic respiratory failure at University Hospital Ghent in Belgium to treat patients with respiratory illness associated with COVID-19.
The company added that major medical centres in Germany, Italy and Spain plan to join the study to evaluate the effect of Leukine (sargramostim, rhu-GM-CSF) on lung function and patient outcomes.
Leukine is a yeast-derived recombinant humanized granulocyte-macrophage colony stimulating factor (rhuGM-CSF) and the only FDA approved GM-CSF. Alveolar macrophages, a cell type found in the lungs, are dependent on GM-CSF for differentiation and normal functioning. GM-CSF is an immunomodulator that plays a critical role in host defense against pathogens and maintaining immune system.
For the treatment of COVID-19 associated acute hypoxic respiratory failure and ARDS, Leukine will be used by the company in nebulized form for direct inhalation or through intravenous administration for patients already on a respirator. Nebulized Leukine has been studied in phase 2 and phase 3 randomized trials in pulmonary conditions that affect alveolar macrophages.
In animal studies, GM-CSF reportedly reduced morbidity and mortality due to acute respiratory distress syndrome (ARDS) from viral pneumonia. In clinical studies, Leukine showed beneficial effects in patients with viral pneumonia, according to the company.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review